Clinical trial
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
NCT00336765 · Kadmon Corporation, LLC, Industry · Completed
Key facts
| NCT number | NCT00336765 |
|---|---|
| Title | Study of XL647 Administered Orally Daily to Patients With Solid Tumors |
| Official title | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors |
| Lead sponsor | Kadmon Corporation, LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | XL647 |
| Enrollment | 31 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Jun 14, 2006 |
| Last update posted | May 13, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: